Altogether, these results indicate superior activity of type II JAK2 and second generation mTOR inhibitors in CRLF2-re/JAK2-mutated Ph-like ALL, secondary to more profound inhibition of collateral JAK2 and 4E-BP1 signaling. Here, JAK2 is linked to acute lymphoblastic leukemia.